odalasvir odalasvir odalasvir (inn, previously known as ach-3102) is an investigational new drug in development for the treatment of hepatitis c. it is an ns5a inhibitor. the ns5a protein serves multiple functions at various stages of the viral life cycle, including viral replication. ns5a also plays a role in the development of interferon-resistance, a common cause of treatment failure. it is under development by achillion pharmaceuticals. odalasvirlegal statuslegal status us: investigational new drug identifiers iupac name dimethyl n,n'-(1,4(1,4)-dibenzenacyclohexaphane- 12,42-diylbis)biscarbamate cas number1415119-52-6 ypubchem cid71474517chemspider34500837uniiovr52k7bdwchemical and physical dataformulac60h72n8o6molar mass1001.286 g·mol−13d model (jsmol)interactive image smiles cc(c)(c(=o)n12cccc2c1c3=nc4=c(n3)c=c(c=c4)c5=c6ccc7=cc(=c(ccc(=c5)c=c6)c=c7)c8=cc9=c(c=c8)n=c(n9)1c2cccc2n1c(=o)(c(c)c)nc(=o)oc)nc(=o)oc inchi inchi=1s/c60h72n8o6/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6/h15-16,19-20,23-30,33-34,41-42,49-54h,7-14,17-18,21-22,31-32h2,1-6h3,(h,61,63)(h,62,64)(h,65,71)(h,66,72)/t41-,42-,49-,50-,51-,52-,53-,54-/m0/s1key:lsybrgmtrkjata-ivewbxrvsa-n